Clinical Trial Update: Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

An open-label, dose-escalation study of Ertumaxomab in HER2/neu-expressing advanced solid tumors (Phase 1/2) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• Ertumaxomab (ertumaxomab)

Snippet

Sponsor: Krankenhaus Nordwest | Conditions: Her2/Neu Positive Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED